Skanska announces decreased scope for facility in Everett, Washington, USA, worth USD 49M, about SEK 510M

Skanska announces that Pfizer has reduced the scope of work on its 25,000 square-meter biomanufacturing facility in Everett, Washington, USA, which Skanska previously was contracted to construct.

The order reduction amounts to USD 49M, about SEK 510M, which will be deducted from the US order bookings for the first quarter 2024.

The initial contract with Seagen, who recently was acquired by Pfizer, was worth USD 215M, about SEK 2.2 billion, and was announced August 4, 2023.

Press release 20240412 US reduced scope Pfizer Contact: Daniela Arellano, Director - Communications Building Telephone Daniela Arellano

Contact:

Andreas Joons

Tel: 0104490494

About us

Skanska is one of the world's leading project development and construction groups. We are active in Europe and North America.